ClinicalTrials.gg
CompletedNCT03914235Updated Apr 29, 2019

Anesthesia Tumescent for Surgical Management of Tenosynovitis.

An interventional study of Tumescent Anesthesia and Lidocaine in Tenosynovitis, sponsored by Instituto Mexicano del Seguro Social. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-29.

Sponsored by Instituto Mexicano del Seguro Social · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2018, registered Apr 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate the effectiveness of the tumescent anesthesia technique in the surgical management of hand tenosynovitis. For this, an open clinical trial was conducted, which included patients with hand tenosynovitis (carpal tunnel syndrome, trigger finger and Quervain syndrome), which were randomly assigned to a group. The control group was released pulleys and ligaments with local anesthetic technique and hemostasis with pneumatic tourniquet; While the study group was released from the pulleys and ligaments with tumescent anesthesia. The study variables were: anesthesia time, trans-surgical bleeding, pain, total procedure time and tissue reperfusion time.

Read the detailed description

Introduction: The WALANT technique (Wide Awake Local Anesthesia No-Torniquet) proposes the use of local anesthesia, epinephrine and tourniquet in the areas of the hand to be repaired, making costs and time and comfort more efficient.

Objective: Evaluation of the effectiveness of the WALANT technique versus regional anesthesia with tourniquet in pain control, surgical management of stenosing tenosynovitis.

Material and methods: Open clinical trial including patients with the trigger finger, tunnel syndrome in the operating room, candidates for surgery, and excluding previous surgeries at the site of the injury, hemodynamic instability, peripheral vascular diseases, smoking, anxiety, or psychiatric diseases. The anesthetic method was applied to the incision sites according to the diagnosis and the proposed procedure. At the end of the test, tumescent solution and control, 1% lidocaine plus pneumatic tourniquet on the forearm at 250mmHg. The main variables were: type of anesthesia and pain during the procedure. Descriptive and inferential statistics were applied (xi2, t-student or Mann-Whitney U).

02

Conditions studied

  • Tenosynovitis

Browse trials for

Keywords

  • Tumescent anesthesia
  • tenosynovitis
  • Visual Analog Scale
  • Tourniquets
  • Epinephrine
03

In context

Tenosynovitis

17 studies on the registry are indexed under Tenosynovitis; 4 are open to participants now.

This study's enrollment of 60 is above the median of 52 across 13 interventional studies indexed under Tenosynovitis.

Browse Tenosynovitis studies →

Lead sponsor

Instituto Mexicano del Seguro Social is the lead sponsor of 126 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right holders of the Mexican Social Security Institute
  • Over 18 years
  • Trigger Finger Diagnosis
  • Diagnosis of Carpal Tunnel Syndrome
  • Diagnosis of Quervain Syndrome
  • Acceptance and signature of

Exclusion criteria

Exclusion Criteria:

  • Necessity for concomitant surgery
  • Previous surgeries on the injured site
  • Hemodynamic instability
  • History of peripheral vascular diseases
  • Do not wish to participate in the study
  • to medication
  • Smoking
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Tumescent anesthesia

    A tumescent solution was prepared; consisting of 40 cc of 0.9% Saline Solution, 10 cc of 2% Lidocaine, 0.4 cc of Epinephrine (1: 1000) and 4 cc of 7.5% Sodium Bicarbonate. This solution was applied in the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc of tumescent solution was injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc of tumescent solution was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Subsequently, 20 minutes were waited for the epinephrine to cause vasoconstriction, and the asepsis of the limb was continued , sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.

    Combination Product: Tumescent Anesthesia · Procedure: Open release of the tendon

  • Active comparator
    Local anesthesia with tourniquet.

    Lidocaine 1% was applied to the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc were injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Afterwards, a pneumatic tourniquet was placed at the level of the forearm at 250 mmHg after exsanguination with a bandage from Esmarch. The asepsis of the limb was continued, sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started. At the end of the surgical procedure, it was closed by planes, a soft bandage was placed, the tourniquet was removed and the patient was taken to recovery.

    Drug: Lidocaine · Device: Pneumatic tourniquet · Procedure: Open release of the tendon

Interventions

  • Combination productTumescent Anesthesia

    A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.

  • Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).

    Also known as: Lidocaine 1%

  • DevicePneumatic tourniquet

    Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.

  • ProcedureOpen release of the tendon

    Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.

06

What researchers measure

Primary outcomes

  1. Procedure pain: Visual Analog Scale

    Evaluated by Visual Analog Scale, A subjective psychometric response scale used to measure distinct behavioral or physiological phenomena based on linear numerical gradient, with values from 0 to 10. In the value 0 the absence or less intensity is located and in 10 the greater intensity of pain.

    Time frame: immediate post surgery

Secondary outcomes

  1. Bleeding

    Bleeding estimated in consensus between anesthesiologist and surgeon, based on the gauze used during surgery

    Time frame: immediate post surgery

  2. Anesthesia application time

    The interval of time in minutes that is required to apply the anesthetic method chosen in the area to be used

    Time frame: at the beginning of the application of anesthesia

07

Study locations

1 site
  • Western Medical Center, Mexican Institute of Social Security
    Guadalajara, Jalisco 44340, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03914235
Responsible party
CLOTILDE FUENTES OROZCO (Investigador de tiempo completo, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
Apr 16, 2019
Start date
Aug 1, 2018
Primary completion
Mar 31, 2019
Completion
Apr 8, 2019
Last update
Apr 29, 2019

Study contacts

Clotilde Fuentes Orozco, PhD
principal investigator · Instituto Mexicano del Seguro Social

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion